BioRegenx, Inc

BioRegenx, Inc

OOTC:BRGX
0.00
USD
+0.00
(-50.00%)
0.00EPS

Share Statistics

As of March 31, 2026, BioRegenx, Inc has 969.02M shares outstanding.

Shares Outstanding969.02M

Financial Position

As of March 31, 2026, BioRegenx, Inc maintains a current ratio of 0.05, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -47.77, indicating conservative leverage, while an interest coverage ratio of -3.39 demonstrates limited ability to service its debt obligations.

Current Ratio0.05
Quick Ratio0.02
Debt / Equity-47.77
Debt / EBITDA-2.11
Interest Coverage-3.39

Financial Efficiency

USD

These figures cover the twelve months ended March 31, 2026. Return on assets (ROA) is negative at -317.96, reflecting losses generated across the asset base. The company generates approximately 321,007.45 in revenue per employee across its workforce of 5.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.74 indicates how many times BioRegenx, Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-317.96
Revenue Per Employee321,007.45
Employee Count5.50
Inventory Turnover2.74

Stock Price Statistics

USD

As of the close on November 4, 2026, BioRegenx, Inc's stock has declined approximately 99.00% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.

52-Week Price Change-99.00%
50-Day Moving Average0.01
200-Day Moving Average0.01

Income Statement

USD

Over the twelve months ended March 31, 2026, BioRegenx, Inc generated 1.77M in revenue and converted that into -1.30M in net income, yielding earnings per share of 0.00. EBITDA reached -1.03M, while operating income came in at -374,788.00.

Revenue1.77M
Gross Profit1.45M
Operating Income-374,788.00
Pretax Income-1.30M
Net Income-1.30M
EBITDA-1.03M
EBIT-1.10M

Balance Sheet

USD

As of March 31, 2026, BioRegenx, Inc holds 45,806.00 in cash and equivalents against 2.17M in total debt, resulting in a net debt position of 2.12M. Total book value stands at -4.53M, with working capital of -3.80M providing operational flexibility.

Cash & Cash Equivalents45,806.00
Total Debt2.17M
Net Debt2.12M
Equity (Book Value)-4.53M
Working Capital-3.80M

Cash Flow

USD

BioRegenx, Inc produced 27,906.00 in operating cash flow over the twelve months ended March 31, 2026. After subtracting -59,057.00 in capital expenditures, free cash flow totaled -31,151.00 - equivalent to 0.00 per share.

Operating Cash Flow27,906.00
Capital Expenditures-59,057.00
Free Cash Flow-31,151.00

Margins

Over the twelve months ended March 31, 2026, BioRegenx, Inc posted a gross margin of 81.90, reflecting its pricing power and cost economics. The operating margin of -21.23 and net profit margin of -73.81 provide insight into operational efficiency.

Gross Margin81.90
Operating Margin-21.23
Pretax Margin-73.81
Profit Margin-73.81
EBITDA Margin-58.08

Stock Splits

BioRegenx, Inc's most recent stock split took place on March 25, 2011 with a 30:1 split ratio.

Last Split Date3/25/2011
Split Ratio30:1